Drugs in MeSH Category Contraceptives, Postcoital, Synthetic

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,195,214
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,780,097
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,166,242
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,495,650
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes	10,166,243
Teva Pharms Usa Inc	MIFEPRISTONE	mifepristone	TABLET;ORAL	211436-001	Aug 3, 2020	AB	RX	No	No

Last updated: July 8, 2026

Market Dynamics and Patent Landscape for Contraceptives, Postcoital, Synthetic (NLM MeSH Class)

What drives the contraceptives and postcoital synthetic drug market dynamics by revenue and volume?

Synthetic contraceptives (oral pills, transdermal patches, vaginal rings, injectables, implants, and emergency contraception) compete on a mix of affordability, adherence, payer access, safety, and time-to-generic. For emergency contraception (postcoital), manufacturers also compete on onset-of-action positioning, switchability in pharmacist-led dispensing, and formulary placement.

Key market structure drivers:

• High payer sensitivity to generic pricing in established oral contraceptive and emergency contraception segments.
• Formulary and benefit-design leverage: coverage tiering for branded long-acting methods versus generic short-cycle oral regimens.
• Adherence economics: long-acting injectables, implants, and rings hold share where dosing cadence is a barrier.
• Safety and labeling differentiation: thrombosis risk narratives, contraindication language, and specific dosing schedules affect formulary and prescriber choice.
• Regulatory pathway speed: ANDA timing and 505(b)(2) reliance on bridging data shapes competitive entry windows.
• Manufacturing/IP barriers: process patents and polymorph/particle-size or solid-state control claims can extend exclusivity beyond formulation.

MeSH “Contraceptives, Postcoital, Synthetic” spans multiple actives and delivery formats, but the patent estate and entry pressure differ materially by whether the product is:

• an emergency contraception single-dose product (often faces faster genericization),
• a monthly-cycle oral contraceptive (more incremental formulation changes but heavy generic competition), or
• a long-acting synthetic contraceptive (method claims and device-like manufacturing can slow entry).

Which patents protect synthetic postcoital and contraceptive products most often?

Patent estates in this MeSH class cluster into six repeatable buckets. The relative weight of each bucket determines how quickly generics can enter.

1) Method-of-use patents

Common claim themes:

• dosing regimens for emergency contraception (timing windows, dose splitting, repeat dosing),
• specific contraceptive scheduling (phasic or extended-cycle schedules),
• patient population claims tied to labeled indications.

Impact:

• Method claims can trigger litigation and delay ANDA approval even when composition-of-matter is no longer enforceable.

2) Formulation and drug-product patents

Most frequent claim targets:

• solid-state forms (polymorphs, solvates, hydrates),
• particle size distribution and milling/precipitation process controls,
• granulation and tablet/pellet architectures,
• film coating compositions and surfactant systems,
• combination products with optimized ratios.

Impact:

• These patents can make “same API” products non-design-aroundable without an alternative formulation route.

3) Process patents

Common claim topics:

• synthesis steps and intermediates,
• purification steps controlling impurities,
• crystallization, polymorph control, and drying conditions,
• scale-up constraints.

Impact:

• Process patents can support injunction risk under generic manufacturing plans.

4) Combination and dose patents

Emergency contraception and contraceptive regimens often use:

• specific combinations (active plus adjunct excipients),
• fixed-dose ratio claims (for co-pack dosing),
• pack and kit configurations.

Impact:

• Dose-specific patents can be harder to design around than generic equivalents that change only excipient grade.

5) Pediatric and alternative route patents

Less common but relevant:

• pediatric dosing frameworks,
• alternate route delivery systems (transdermal, vaginal).

Impact:

• Route patents can lock out alternative administration forms.

6) Device-adjacent patents (delivery systems)

For rings and injectables/implants:

• applicator and release system features,
• polymer matrices and release kinetics.

Impact:

• This category can block “drop-in” competitors.

What is the Orange Book status of synthetic postcoital and contraceptive drugs, and how does it predict generic entry?

Orange Book status is the practical proxy for patent-driven delay because it ties exclusivity listings and submitter patents to FDA application review.

The Orange Book generally indicates:

• Approved drug products with therapeutic equivalence codes.
• Listed patents: composition-of-matter, method-of-use, and formulation or process depending on the NDA submission.
• Exclusivity flags: new chemical entity, new clinical studies, pediatric exclusivity, orphan exclusivity (when applicable).

Business interpretation:

• Products with multiple listed patents across categories show longer “litigation runway” and higher frequency of Paragraph IV.
• Products with only one or two late-listed patents often see faster settlement or earlier generic launches.

Data prerequisite note: Building a correct Orange Book by-drug table requires the specific NDA/BLA numbers and Orange Book listing sets for each drug in this MeSH class. Without those, a complete, accurate estate-by-product status mapping cannot be produced.

When do contraceptives and postcoital synthetic drugs lose exclusivity: patent expiry vs FDA exclusivity?

Exclusivity and patent expiry are different clocks.

Two primary timing regimes:

1. Patent-driven exclusivity
   • composition-of-matter expiration blocks direct generic entry until it clears.
   • method-of-use and formulation patents can block ANDA approvals through litigation or settlement.
2. FDA exclusivity-driven exclusivity
   • 5-year NCE, 3-year new clinical study, 7-year pediatric (when triggered), and additional exclusivities depending on submission type.

Business rule:

• Patent expiry without an Orange Book “listed patent” outcome may not stop an ANDA.
• Orange Book listed patents still in force can delay generic approvals even if the underlying chemistry patent has expired, if method-of-use and formulation patents remain.

Data prerequisite note: A timeline with exact expiry dates per active ingredient requires the NLM MeSH-linked drug set and each product’s listed patents and exclusivity codes.

How many patents cover synthetic postcoital and contraceptive actives, and what is the estate profile by claim type?

Estate density can be measured by:

• number of Orange Book listed patents per NDA product,
• breadth across claim categories (MoU vs formulation vs process),
• number of “active” patents still in force on a given reference date.

Typical profiles by segment:

• Emergency contraception: estates often emphasize formulation/process and dosing regimens, with fewer “deep” parallel patents but more visible Paragraph IV challenges once any entry barrier clears.
• Established contraceptive or combination oral products: estates tend to include formulation improvements and updated schedules, while original composition IP often faces earlier clearance.
• Long-acting synthetic methods: fewer products but more complex delivery and process claims, increasing design-around cost.

Data prerequisite note: Quantifying “how many” patents and giving estate profiles requires a specific drug list (NDA numbers) and each patent listing’s legal status.

Which companies challenge contraceptives and postcoital synthetic drugs via Paragraph IV, and what has happened in settlements?

Paragraph IV challenges are the competitive event generator. The most frequent pattern:

• ANDA filers select a target drug with a large Orange Book patent list and argue non-infringement or invalidity.
• If at least one listed patent is asserted, litigation can trigger a settlement with an agreed generic launch date.

Settlement characteristics common in this MeSH class:

• agreed entry date timed to the last-to-expire asserted patent,
• license provisions for brand-to-generic tech transfer when formulation/process patents are central,
• stipulations on label wording tied to method-of-use constraints.

Data prerequisite note: Identifying the exact challenger companies and settlement outcomes requires the case docket set (district court, plaintiffs, ANDA applicants) tied to specific actives.

What patent litigation affects synthetic contraceptives and postcoital products: injunction risk and damages?

Patent litigation affects market entry through:

• injunction risk if the brand can secure a court order related to enforceable patents,
• “launch at risk” outcomes when generics proceed without resolving infringement findings,
• settlement timing that determines the first non-brand sale.

Typical legal outcomes that matter for market entry:

• partial stays pending appeal,
• damages caps and ongoing royalties if design-around is partial,
• stipulations to withdraw certain claims if a generic changes composition or process.

Data prerequisite note: A litigation table with case names and patent numbers requires specific known cases.

How do formulation patents for synthetic postcoital and contraceptive drugs shape generic design-around strategies?

Generic entrants design around based on which patent bucket blocks approval:

If blocked by formulation patents, strategies include:

• switching solid-state form,
• changing particle size distribution via different crystallization steps,
• substituting surfactant systems and coating packages,
• altering tablet/pellet architecture and excipient ratios where permitted.

If blocked by process patents, strategies include:

• changing synthetic route to reach the same API with different intermediates,
• changing crystallization/drying conditions to avoid claimed process parameters,
• adopting different impurity control targets tied to purification claims.

If blocked by method-of-use patents, strategies include:

• changing labeling and dosing narrative,
• limiting indication scope to avoid infringing regimens,
• pursuing a 505(b)(2) path with different clinical bridging.

Data prerequisite note: Mapping exact formulation-patent claim coverage to actual generic launch choices requires per-drug claim language and known ANDA formulations.

How does 505(b)(2) compare with ANDA for synthetic contraceptives and emergency contraception entry?

In this segment:

• 505(b)(2) can be used to leverage published literature or bridging studies to support a new formulation, delivery system, or dosing schedule.
• ANDA is typical for pure generics with bioequivalence.

Competitive use cases:

• brand follow-on products can use 505(b)(2) to update formulation or schedule, then build new Orange Book listings.
• generic manufacturers may use 505(b)(2) to avoid the patent set that blocks ANDA, especially when formulation/process claims are strong.

Data prerequisite note: A correct 505(b)(2) vs ANDA comparison for this MeSH class requires per-product NDA application data.

Which synthetic contraceptives face the highest biosimilar or biologic-style risk?

This MeSH class is labeled “synthetic,” so biologics/biosimilars are not the expected category driver. Risk typically comes from:

• long-acting release systems that may use polymeric technologies,
• combination regimens that create method-of-use challenges,
• formulation patents that behave like “biologic process” barriers in practical terms (hard to reproduce).

If a product includes:

• synthetic active hormones with standard chemical manufacturing, biosimilar frameworks do not apply.
• no biologic is indicated, the competitive risk is mainly generic ANDA plus patent litigation.

Data prerequisite note: A biologic/biosimilar risk assessment requires confirmation that any products in the target drug set are biologics or are regulated outside small-molecule pathways.

What commercial launch scenarios exist for generics if patent barriers clear for synthetic postcoital and contraceptive drugs?

Once the Orange Book listed patents or litigation barriers clear, common commercial scenarios:

• Rapid generic entry with substitution: multiple ANDAs launch within a short window, compressing net prices quickly.
• Label carve-outs: generics may enter with narrower dosing instructions aligned to avoid method-of-use infringement allegations.
• Supply-driven winner-take-most: even after exclusivity clearance, production capacity determines early market share.
• Payer-led switching: pharmacy benefit managers accelerate substitution after FDA approval and patent clearance.

Commercial risk factors:

• remaining unasserted patents can still create further delays if brands reassert or amend claims through continuations.
• formulation design-around may produce different dissolution or stability behavior affecting launch readiness.

Data prerequisite note: Scenario modeling with dates and likely market entrants requires the specific drug set and known launch timelines.

Key Takeaways

• Patent estates in “Contraceptives, Postcoital, Synthetic” typically hinge on method-of-use, formulation, and process claims that determine whether ANDA filers can clear Orange Book listed patents.
• Market dynamics are driven by payer substitution economics and the speed of generic approval once patent barriers clear, with emergency contraception often showing faster competitive pressure once key listings resolve.
• A complete, decision-ready estate-and-timeline map requires drug-specific Orange Book listing sets, NDA application IDs, and litigation/settlement records. Without those identifiers, a correct per-drug market and patent landscape cannot be produced.

FAQs

1. What Orange Book patent categories most often block ANDA approval for contraceptive products?
2. How do dosing schedule and labeling revisions affect infringement risk for postcoital emergency contraception?
3. What claim types in formulation patents are hardest for generic manufacturers to design around?
4. Do process patents for synthetic hormone APIs materially delay emergency contraception generic launches?
5. How do settlement agreements typically set the first permissible generic launch date in this therapeutic area?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA (accessed 2026-07-08).